Previous close | 3.6000 |
Open | 3.1500 |
Bid | 2.0000 |
Ask | 3.9500 |
Strike | 77.00 |
Expiry date | 2024-06-07 |
Day's range | 3.1500 - 3.1500 |
Contract range | N/A |
Volume | |
Open interest | 115 |
Most bosses are defeating shareholder attempts so far this year to tamp down their pay. The question now is whether Tesla CEO Elon Musk can do the same.
The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.